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Elevated blood glucose promotes lipogenesis via activating SREBP transcription factors. Tumors exhibit
increased glucose uptake and lipogenesis, but the mechanisms controlling this are poorly understood. In
this issue of Cancer Cell, Cheng and colleagues find that glucose activates SREBP by stabilizing SCAP, a
central regulator of the SREBP pathway.Alteration of cellular metabolism is
a hallmark of cancer. Tumors exhibit
increased aerobic glycolysis and elevated
lipogenesis to supply energy and lipids,
such as fatty acids and cholesterol,
required for cell growth (Menendez and
Lupu, 2007). In addition to its role in en-
ergy production, glucose is a precursor
for lipid synthesis. In tissues such as
liver and adipose, insulin transduces a
signal from glucose to the sterol regulato-
ry element-binding proteins (SREBPs) to
induce lipogenesis and promote energy
storage (Shao and Espenshade, 2012).
Although known signaling cascades
downstream of oncogenic drivers such
as RAS or TOR stimulate lipogenesis (Ric-
oult et al., 2015), whether glucose supply
independently activates lipogenesis is
unclear.
SREBP transcription factors are cen-
tral regulators of cellular lipogenesis
(Shao and Espenshade, 2012). These
endoplasmic reticulum (ER) membrane-
bound transcription factors bind to
the SREBP cleavage activating protein
(SCAP), which controls their activity
(Figure 1). Under repressed conditions,
SCAP binds to the ER-resident protein
INSIG, and the SCAP-SREBP complex
is retained in the ER. When lipid supply
is low, the SCAP-SREBP complex traf-
fics to the Golgi, where two proteases
release the N-terminal transcription fac-
tor domain of SREBP, allowing it to enter
the nucleus and stimulate gene expres-
sion. SREBP family members activate
synthesis and the uptake of fatty acids,
triglycerides, and cholesterol. Although
SCAP is essential for SREBP activation,
few regulatory inputs are known (Shao
and Espenshade, 2012). SCAP responds
directly to levels of cholesterol in the ER,
which serves as an end product feed-
back signal from cholesterol synthesis548 Cancer Cell 28, November 9, 2015 ª201(Figure 1). Cholesterol binds SCAP,
promoting INSIG binding and ER reten-
tion. In addition, SCAP levels decrease
when SREBP cleavage is blocked in
the Golgi through a lysosome-depen-
dent pathway (Shao and Espenshade,
2014). However, to date, no major nutri-
tional regulation of SCAP has been
reported.
SREBP function is best studied in the
liver, where SREBPs contribute to whole
body lipid homeostasis. More recently,
knowledge that tumors are highly lipo-
genic has led investigators to examine
the function of SREBP in cancer, with
efforts initially focusing on glioblas-
toma (GBM). These studies demonstrate
that the EGFR-Akt pathway stimulates
SREBP-dependent lipogenesis and
SREBP is required for GBM cell survival
and tumor growth (Griffiths et al., 2013;
Guo et al., 2009). Together with work in
breast cancer cells (Ricoult et al., 2015),
these results highlight an important role
for the SREBP pathway in tumor growth,
making it an interesting therapeutic
candidate.
In this issue of Cancer Cell, Cheng
et al. (2015) build on their previous
studies and look for connections be-
tween glucose supply and elevated
lipogenesis observed in GBM. The au-
thors discover that glucose has an
insulin-independent pathway to control
SCAP and promote lipogenesis. Their
initial observation was that SREBP
activation requires glucose in GBM
cells and SCAP levels decrease dramat-
ically in low glucose. Mechanistic exper-
iments show that glucose controls
SCAP because of its requirement as
a precursor of N-acetylglucosamine in
N-glycosylation and that low glucose
reduced SCAP glycosylation. Inhibitors
of N-linked, but not O-linked, glycosyla-5 Elsevier Inc.tion decrease SCAP levels and prevent
SREBP activation. Earlier studies by
the Brown and Goldstein laboratories
showed that SCAP is an 8 trans-
membrane protein that contains three
N-glycosylation sites in its luminal loops
(Figure 1). The presence of any one site
is sufficient to support SREBP activity
(Nohturfft et al., 1998). Here, the authors
demonstrate that mutation of all three
sites leads to proteasome-dependent
degradation of the non-glycosylated
SCAP mutant (SCAP-QQQ) and a fail-
ure to activate SREBP. Interestingly,
wild-type, glycosylated SCAP showed
reduced binding to the negative regu-
lator INSIG compared to SCAP-QQQ,
suggesting that glycosylation status
also may influence INSIG retention of
SCAP (Figure 1).
EGFR signaling stimulates glucose
uptake and activates SREBP in GBM
cells (Guo et al., 2009). The authors
next addressed whether these effects
required glucose. Glucose activated
SREBP and increased SCAP in the
absence of growth factor. EGF had no
effect on SREBP activity alone, but
addition of glucose strongly increased
SCAP and activated SREBP. As ex-
pected, SCAP was required for EGF
activation of SREBP, and inhibition of
N-glycosylation both reduced SCAP
and prevented EGF-stimulated activa-
tion of SREBP. These results suggest
that one function of EGFR signaling is
to increase glucose uptake to support
SCAP glycosylation.
Previous studies showed the impor-
tance of lipogenesis and SREBP activa-
tion for GBM tumor growth (Griffiths
et al., 2013; Guo et al., 2009). The au-
thors investigated the role of SCAP glyco-
sylation in vivo using both subcu-
taneous and orthotopic xenograft mouse
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Figure 1. Glucose-Induced Activation of SREBP and Lipogenesis
Glucose promotes lipogenesis by (1) generating acetyl-CoA, the substrate for
lipogenesis; (2) stimulating pancreatic insulin secretion, which activates
SREBP-dependent lipogenic gene expression; and (3) generating UDP-
GlcNAc required for SCAP N-glycosylation. Glycosylation of SCAP prevents its
degradation and promotes disassociation from the ER-resident protein INSIG,
resulting in SREBP activation. Abbreviations: INSIG, insulin-induced gene;
UDP-GlcNAc; uridine diphosphate N-acetylglucosamine; acetyl-CoA, acetyl
coenzyme A.
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SCAP decreased tumor
weight and prolonged sur-
vival of intracranial tumor-
bearing mice. To investigate
SCAP glycosylation specif-
ically, the authors overex-
pressed either wild-type
SCAP or the SCAP-QQQ
mutant in GBM cells. Inter-
estingly, overexpression of
wild-type SCAP increased
tumor weight relative to
control and decreased sur-
vival in the orthotopic model.
Overexpression of SCAP-
QQQ had dominant effects,
decreasing tumor weight
and prolonging survival con-
sistent with its inability toactivate SREBP-dependent lipogenesis.
These findings are significant and demon-
strate both that SCAP glycosylation is
required to support tumor growth and,
perhaps more importantly, that SCAP is
limiting for tumor growth and pathogen-
esis in vivo.
Collectively, these experiments outline
a pathway by which the requirement of
glucose for SCAP N-glycosylation per-
mits glucose supply to control SREBP-
dependent lipogenesis. Growth factor
signaling stimulates glucose uptake
for energy production, but this study
describes another mechanism by which
glucose additionally drives lipogenesis,
adding to our understanding of why
these two processes coexist in
tumorigenesis.
This study raises a number of impor-
tant questions that require further inves-
tigation. These experiments show that
low glucose regulates SCAP protein
levels, but to what extent do physio-
logical changes in glucose influence
SCAP glycosylation and function?
Blood glucose concentrations are tightly
controlled and such low glucose may
only occur in poorly vascularized tumors.
Does this signaling pathway function innormal tissues and do non-mitotic
cells, such as hepatocytes, respond to
glucose in a similar manner? Further-
more, does elevated glucose regulate
SCAP in the setting of diabetes? Could
this mechanism explain links between
diabetes and disease progression in
particular cancers? Finally, cancer cells
frequently increase glutamine uptake,
and glutamine can also serve as a pre-
cursor for N-acetylglucosamine (Metallo
and Vander Heiden, 2010). Can gluta-
mine supply also signal to SCAP and
lipogenesis?
This paper highlights the importance of
lipogenesis in tumor growth and iden-
tifies SCAP as a key regulator in this
context. To date, the requirement of the
SREBP pathway for tumor growth has
been studied in GBM, breast, and pros-
tate cancer cells (Krycer et al., 2012). It
will be essential to expand these studies
to see how general the requirement for
the SREBP pathway is. Regarding this
point, the authors demonstrate that
glucose controls SCAP levels in cell lines
of multiple cancer types.
Finally, this study reports the first nutri-
tional stimulus to control SCAP. From a
mechanistic standpoint, it will be impor-Cancer Cell 28, November 9,tant to know the molecular
machinery required for pro-
teasome-dependent degra-
dation of non-glycosylated
SCAP.Activationof a required
E3 ubiquitin ligase could
serve as a therapeutic strat-
egy to downregulate SCAP
and inhibit lipogenesis. In
addition, while general glyco-
sylation inhibitors are likely
toxic, specific inhibitors of
SCAP glycosylation may
block lipogenesis. Chemical
inhibitors of SCAP will impact
not only cancer treatment,
but also other prevalentmeta-
bolic diseases such as nonal-
coholic fatty liver disease that
requires SCAP, making thedevelopment of specific SCAP inhibitors
a priority.REFERENCES
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